1. Progressive multifocal leukoencephalopathy and Creutzfeldt-Jakob disease: population-wide incidences, comorbidities, costs of care, and outcomes.
- Author
-
Bakal JA, Charlton CL, Hlavay B, Jansen GH, Svenson LW, and Power C
- Subjects
- Adult, Aged, Aged, 80 and over, Alberta epidemiology, Cerebrovascular Disorders diagnosis, Cerebrovascular Disorders economics, Cerebrovascular Disorders mortality, Chronic Disease, Comorbidity, Creutzfeldt-Jakob Syndrome diagnosis, Creutzfeldt-Jakob Syndrome economics, Creutzfeldt-Jakob Syndrome mortality, Female, HIV Infections diagnosis, HIV Infections economics, HIV Infections mortality, Humans, Incidence, Leukoencephalopathy, Progressive Multifocal diagnosis, Leukoencephalopathy, Progressive Multifocal economics, Leukoencephalopathy, Progressive Multifocal mortality, Male, Middle Aged, Survival Analysis, Cerebrovascular Disorders epidemiology, Cost of Illness, Creutzfeldt-Jakob Syndrome epidemiology, HIV Infections epidemiology, Leukoencephalopathy, Progressive Multifocal epidemiology
- Abstract
Neurological disorders associated with chronic infections are often progressive as well as challenging to diagnose and manage. Among 4.4 million persons from 2004 to 2019 receiving universal health, progressive multifocal leukoencephalopathy (PML, n = 58) and Creutzfeldt-Jakob disease (CJD, n = 93) cases were identified, revealing stable yearly incidence rates with divergent comorbidities: HIV/AIDS affected 37.8% of PML cases while cerebrovascular disease affected 26.9% of CJD cases. Most CJD cases died within 1 year (73%) although PML cases lived beyond 5 years (34.1%) despite higher initial costs of care. PML and CJD represent important neurological disorders with evolving risk variables and impact on health care.
- Published
- 2021
- Full Text
- View/download PDF